-
The Future Of Nano Technology
Categories
- Ai
- Alan Watts
- Anatomy
- Andropause
- Anti-Aging Medicine
- Arthritis
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ataxia
- Autism
- Biochemistry
- BioEngineering
- Biotechnology
- Bitcoin
- Chemistry
- Cryonics
- Cryptocurrency
- David Sinclair
- Dementia
- Diet Science
- Diseases
- Eczema
- Elon Musk
- Futurism
- Gene Medicine
- Gene therapy
- Gene Therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Healthy Lifestyle
- Healthy Living
- HGH Physicians
- Hormone Optimization
- Hormone Replacement Therapy
- Hormone Replacement Treatment
- Human Genetic Engineering
- Human Immortality
- Human Longevity
- Human Reproduction
- Hypogonadism
- Hypopituitarism
- Hypothyroidism
- Immortality
- Immortality Medicine
- Inflammation
- Injectable Growth Hormone
- Integrative Medicine
- Life Skills
- Longevity
- Longevity Medicine
- Low T
- Machine Learning
- Mars Colony
- Medical School
- Menopause
- multiple-sclerosis
- Nano Medicine
- Nanomedicine
- Nanotechnology
- Neurology
- Parkinson's disease
- Pharmacogenomics
- Protein Folding
- Psoriasis
- Quantum Computing
- Regenerative Medicine
- Resveratrol
- Sermorelin Physicians
- Singularity
- Spacex
- Stem Cell Therapy
- Stem Cells
- Stemcell Therapy
- Testosterone
- Testosterone Physicians
- Transhuman
- Transhumanism
- Transhumanist
- Uncategorized
- Veganism
- Vegetarianism
- Vitamin Research
- Wellness
-
Recent Posts
- Polyplus Launches Innovative Plasmid for AAV Vector Production, Strengthening Its Position in Biologic and Cell … – BSA bureau
- Orchard Sets $4.25M US Price for Gene Therapy Lenmeldy on Heels of Approval – BioSpace
- Stem Cell Editing Repairs Severe Immunodeficiency – The Scientist
- Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in … – GlobeNewswire
- New Gene Therapy for Rare MDL to Cost $4.25 Million – Managed Healthcare Executive
Archives
Popular
Search Immortality Topics: |
Category Archives: Global News Feed
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and…
– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options –
Read the original here:
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and...
Posted in Global News Feed
Comments Off on Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and…
Tempest Reports Year End 2022 Financial Results and Provides Business Update
BRISBANE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the year ended December 31, 2022 and provided a corporate update.
See the original post here:
Tempest Reports Year End 2022 Financial Results and Provides Business Update
Posted in Global News Feed
Comments Off on Tempest Reports Year End 2022 Financial Results and Provides Business Update
CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Continue reading here:
CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
Posted in Global News Feed
Comments Off on CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States
See the article here:
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Posted in Global News Feed
Comments Off on Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer
Go here to see the original:
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Posted in Global News Feed
Comments Off on AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process
The rest is here:
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
Posted in Global News Feed
Comments Off on Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment